TOVX Fundamental Analysis - THERIVA BIOLOGICS INC

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to TOVX. TOVX was compared to 558 industry peers in the Biotechnology industry. TOVX may be in some trouble as it scores bad on both profitability and health. TOVX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TOVX has reported negative net income.

TOVX had a negative operating cash flow in the past year.

In the past 5 years TOVX always reported negative net income.

TOVX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TOVX has a worse Return On Assets (-77.15%) than 69.18% of its industry peers.

TOVX has a worse Return On Equity (-160.11%) than 64.34% of its industry peers.

		Industry Rank	Sector Rank
ROA	-77.15%
ROE	-160.11%
ROIC	N/A

ROA(3y)-44.56%

ROA(5y)-63.19%

ROE(3y)-72.49%

ROE(5y)-81.87%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, TOVX has less shares outstanding

Compared to 5 years ago, TOVX has more shares outstanding

Compared to 1 year ago, TOVX has a worse debt to assets ratio.

2.2 Solvency

TOVX has an Altman-Z score of -16.36. This is a bad value and indicates that TOVX is not financially healthy and even has some risk of bankruptcy.

TOVX has a worse Altman-Z score (-16.36) than 81.90% of its industry peers.

TOVX has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.10, TOVX is doing worse than 65.41% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.1
Debt/FCF	N/A
Altman-Z	-16.36

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.53 indicates that TOVX should not have too much problems paying its short term obligations.

TOVX's Current ratio of 1.53 is on the low side compared to the rest of the industry. TOVX is outperformed by 81.18% of its industry peers.

A Quick Ratio of 1.53 indicates that TOVX should not have too much problems paying its short term obligations.

TOVX has a worse Quick ratio (1.53) than 80.82% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.53
Quick Ratio	1.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for TOVX have decreased strongly by -1688.20% in the last year.

EPS 1Y (TTM)-1688.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%79.33%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TOVX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.64% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y76.93%

EPS Next 2Y32.61%

EPS Next 3Y21.64%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

TOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

TOVX's earnings are expected to grow with 21.64% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.61%

EPS Next 3Y21.64%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for TOVX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (6/2/2025, 8:04:00 PM)

Premarket: 0.516 +0.03 (+5.61%)

0.4886

+0.02 (+4.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-14 2025-05-14/bmo

Earnings (Next)08-11 2025-08-11

Inst Owners16.36%

Inst Owner Change453.12%

Ins Owners0.48%

Ins Owner Change0%

Market Cap4.00M

Analysts82.86

Price Target6.12 (1152.56%)

Short Float %2.11%

Short Ratio0.11

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)56.44%

Min EPS beat(2)49.15%

Max EPS beat(2)63.73%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)42.62%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.26
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-20.68

EYN/A

EPS(NY)-5.9

Fwd EYN/A

FCF(TTM)-2.05

FCFYN/A

OCF(TTM)-2.05

OCFYN/A

SpS0

BVpS1.89

TBVpS-0.32

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-77.15%
ROE	-160.11%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-44.56%

ROA(5y)-63.19%

ROE(3y)-72.49%

ROE(5y)-81.87%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.1
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.53
Quick Ratio	1.53
Altman-Z	-16.36

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)94.56%

Cap/Depr(5y)59.96%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-1688.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%79.33%

EPS Next Y76.93%

EPS Next 2Y32.61%

EPS Next 3Y21.64%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y14.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y15.6%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y15.05%

OCF growth 3YN/A

OCF growth 5YN/A

THERIVA BIOLOGICS INC (TOVX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens